Room With a View

Overview

Journal Circ Cardiovasc Imaging

Specialties Cardiology & Vascular Diseases
Radiology

Date 2018 Oct 26

PMID 30354505

Authors

Lai-Ming Yung

Paul B Yu

Affiliations

Soon will be listed here.

References

Rehman J, Archer S . A proposed mitochondrial-metabolic mechanism for initiation and maintenance of pulmonary arterial hypertension in fawn-hooded rats: the Warburg model of pulmonary arterial hypertension. Adv Exp Med Biol. 2010; 661:171-85. DOI: 10.1007/978-1-60761-500-2_11. View

Michelakis E, Gurtu V, Webster L, Barnes G, Watson G, Howard L . Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Sci Transl Med. 2017; 9(413). DOI: 10.1126/scitranslmed.aao4583. View

Tatebe S, Fukumoto Y, Oikawa-Wakayama M, Sugimura K, Satoh K, Miura Y . Enhanced [18F]fluorodeoxyglucose accumulation in the right ventricular free wall predicts long-term prognosis of patients with pulmonary hypertension: a preliminary observational study. Eur Heart J Cardiovasc Imaging. 2014; 15(6):666-72. DOI: 10.1093/ehjci/jet276. View

Letourneau M, Nguyen Q, Harel F, Fournier A, Dupuis J . PulmoBind, an adrenomedullin-based molecular lung imaging tool. J Nucl Med. 2013; 54(10):1789-96. DOI: 10.2967/jnumed.112.118984. View

Zhao L, Ashek A, Wang L, Fang W, Dabral S, Dubois O . Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments. Circulation. 2013; 128(11):1214-24. DOI: 10.1161/CIRCULATIONAHA.113.004136. View

Cool C, Stewart J, Werahera P, Miller G, Williams R, Voelkel N . Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol. 1999; 155(2):411-9. PMC: 1866857. DOI: 10.1016/S0002-9440(10)65137-1. View

Yung L, Nikolic I, Paskin-Flerlage S, Pearsall R, Kumar R, Yu P . A Selective Transforming Growth Factor-β Ligand Trap Attenuates Pulmonary Hypertension. Am J Respir Crit Care Med. 2016; 194(9):1140-1151. PMC: 5114445. DOI: 10.1164/rccm.201510-1955OC. View

Marsboom G, Wietholt C, Haney C, Toth P, Ryan J, Morrow E . Lung ¹⁸F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012; 185(6):670-9. PMC: 3326289. DOI: 10.1164/rccm.201108-1562OC. View

Hoeper M, Barst R, Bourge R, Feldman J, Frost A, Galie N . Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013; 127(10):1128-38. DOI: 10.1161/CIRCULATIONAHA.112.000765. View

10.

Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang S, Bandoh S . Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007; 34(10):1610-6. DOI: 10.1007/s00259-007-0449-7. View

11.

Shields A, Grierson J, Dohmen B, Machulla H, Stayanoff J, Obradovich J . Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998; 4(11):1334-6. DOI: 10.1038/3337. View

12.

Benza R, Miller D, Barst R, Badesch D, Frost A, McGoon M . An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012; 142(2):448-456. DOI: 10.1378/chest.11-1460. View

13.

Yap C, Czernin J, Fishbein M, Cameron R, Schiepers C, Phelps M . Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest. 2006; 129(2):393-401. DOI: 10.1378/chest.129.2.393. View

14.

Long L, Crosby A, Yang X, Southwood M, Upton P, Kim D . Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation. 2009; 119(4):566-76. DOI: 10.1161/CIRCULATIONAHA.108.821504. View

15.

Tolle J, Waxman A, Van Horn T, Pappagianopoulos P, Systrom D . Exercise-induced pulmonary arterial hypertension. Circulation. 2008; 118(21):2183-9. PMC: 2767322. DOI: 10.1161/CIRCULATIONAHA.108.787101. View

16.

Morrell N, Yang X, Upton P, Jourdan K, Morgan N, Sheares K . Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation. 2001; 104(7):790-5. DOI: 10.1161/hc3201.094152. View

17.

Houssaini A, Abid S, Mouraret N, Wan F, Rideau D, Saker M . Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. Am J Respir Cell Mol Biol. 2013; 48(5):568-77. PMC: 4901163. DOI: 10.1165/rcmb.2012-0429OC. View

18.

Hoeper M, McLaughlin V, Barbera J, Frost A, Ghofrani H, Peacock A . Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respir Med. 2016; 4(11):894-901. DOI: 10.1016/S2213-2600(16)30307-1. View

19.

Oikawa M, Kagaya Y, Otani H, Sakuma M, Demachi J, Suzuki J . Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. J Am Coll Cardiol. 2005; 45(11):1849-55. DOI: 10.1016/j.jacc.2005.02.065. View

20.

Ashek A, Spruijt O, Harms H, Lammertsma A, Cupitt J, Dubois O . 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung. Circ Cardiovasc Imaging. 2018; 11(8):e007402. DOI: 10.1161/CIRCIMAGING.117.007402. View